Ligand Pharmaceuticals

Last updated
Ligand Pharmaceuticals Incorporated
Company type Public company
IndustryBiopharmaceuticals
FoundedSeptember 1987;36 years ago (1987-09)
FounderBrook Byers [1]
Headquarters San Diego, California, U.S.
Key people
John Higgins
(CEO)
Revenue US$141 million (2017) [2]
Number of employees
155 (2020) [3]
Website ligand.com

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. [4] Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.[ citation needed ]

Contents

The company has been the subject of multiple regulatory investigations, [5] negative shorts-seller reports [6] and class action lawsuits amid allegations of securities fraud. [7] [8] [9] [10]

In 2018 its CEO was listed among the top five highest paid CEOs in San Diego. [11]

Business

Ligand Pharmaceutical develops or acquires royalty-generating assets comprising numerous technologies, therapies and drugs. [12] The drugs for which it receives royalties include Kyprolis, Promacta, Melphalan and Baxdela. [13]

As of 2015, Ligand Pharmaceuticals was partnered with approximately 120 pharmaceutical companies, which include Captisol and its partnerships. [14] Captisol, a Ligand indication, is a chemically modified clathrate compound of the cyclodextrin class designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. [15]

History

Ligand Pharmaceuticals was founded, as Progenix Inc., in 1987 by Brook Byers and went public in late 1992. [16] Its first CEO was Howard Birndorf, succeeded by David Robinson, both of whom focused on developing drugs based on orphan nuclear receptors. [5]

In September 2005, the company was delisted by the NASDAQ following "accounting irregularities," that resulted in late filings. [17] The same month the Securities and Exchange Commission of the company's financial reporting, which was characterized as "questionable," and resulted in a "lengthy scandal" according to The San Diego Union-Tribune . [18] [19] In October 2005, the company as well as the Board of Directors and certain officers were named as defendants in a shareholder derivative lawsuit alleging breach of fiduciary duty [8] and that Ligand artificially inflated its revenue by engaging in “channel stuffing.” [7] In June 2006, Ligand agreed to pay $12.2 million to settle a securities class-action lawsuit as well as related state and federal shareholder derivative lawsuits that alleged the company had engaged in accounting improprieties. [7]

In addition to accounting irregularities, by 2006 the company had reported no profits despite some of the drugs the company developed being approved, and dissident shareholders, including Dan Loeb, forced Robinson out.[ citation needed ] He was replaced as CEO by Henry F. Blissenbach who sold all the company's commercial operations and cut the workforce.[ citation needed ] In January 2007 John Higgins, a former investment banker, was brought in as CEO. He changed the company's strategy to one of acquiring candidate drugs and forming partnerships to develop them further. [5]

In the late 2000s, the company used its capital to acquire other companies including Neurogen, Pharmacopeia biotechnology, Metabasis Therapeutics and Cydex Pharmaceuticals. CEO Higgins stated that the result of the purchases was a portfolio of some 60 new drug candidates, partnerships with pharmaceutical companies and other assets. [5]

In November 2016, The Shareholder Foundation filed a class action lawsuit against Ligand, alleging the company had engaged in securities fraud by making false and misleading statements, overstating the value of its assets, mis-classifying its debt, and by failing to maintain control over its accounting. [9] A separate class-action lawsuit, filed the same month, which named Ligand CEO John Higgins and CFO Matthew Korenberg, alleged, the company's "wrongful acts and omissions" led to a "precipitous" decline the market value of the company's stock and that the company's investors had suffered "significant losses and damages." [20]

In December 2016, Ligand was named as a defendant in multiple securities class action lawsuits, alleging the company had engaged in securities fraud by making false or misleading statements about its financial condition and its ability to control its reporting. [21] [22]

In July 2018, Ligand was sued by investors, including Citadel, for $3.8 billion, alleging the company unfairly modified its agreements with investors and never filed the amendment with the U.S. Securities and Exchange Commission. [10]

Short Seller

In June 2014, Emmanuel Lemelson, while shorting Ligand stock, published 56 pages of reports that criticized the company as a fraud and alleged the company was insolvent. [6] The commentary caused a $500 million drop in the company's market capitalization and a profit of $1.4 million to Lemelson. Ligand executives, former high ranking-SEC lawyer Brad Bondi and congressmen Duncan Hunter subsequently lobbied the U.S. Securities and Exchange Commission to charge Lemelson. [23] [24] According to company emails and trial testimony, Ligand CEO John Higgins wanted Lemelson "silenced for good." [23] [25] In September 2018, the SEC sued Lemelson for an alleged "manipulative scheme" to defraud investors. On November 5, 2021, a federal jury rejected the allegations in a mixed verdict, [26] which cleared Lemelson of the commentary on Ligand in his reports but did find misstatements, including about a different company, Viking Therapeutics. [27] [28] Lemelson was subsequently fined $160,000. [29]

Related Research Articles

Biovail Corporation was a Canadian pharmaceutical company, operating internationally in all aspects of pharmaceutical products. Its major production facility was located in Steinbach, Manitoba. It merged with Valeant Pharmaceuticals International in 2010.

The Private Securities Litigation Reform Act of 1995, Pub. L.Tooltip Public Law  104–67 (text)(PDF), 109 Stat. 737 ("PSLRA") implemented several substantive changes in the United States that have affected certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation, and awards fees and expenses.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

Life Partners, Inc. is a life settlement provider headquartered in Waco, Texas. LPI's parent company, Life Partners Holdings, Inc., delisted from the NASDAQ, currently trades on the OTCPK under the ticker LPHI.Q. This follows the company seeking Chapter 11 bankruptcy protection, resulting from a total of $46.9 million in penalties levied against the company and two of its officers.

China Medical Technologies, Inc. (CMED) was a Cayman Islands corporation based in China, currently in liquidation following fraud allegations. It purported to develop, manufacture, and market advanced in vitro diagnostic ("IVD") products using enhanced chemiluminescence ("ECLIA") technology, fluorescent in-situ hybridization ("FISH") technology, and surface plasmon resonance (“SPR”) technology to detect and monitor various diseases and disorders.

<span class="mw-page-title-main">Steve Berman (lawyer)</span> American lawyer

Steve W. Berman is an American plaintiff's lawyer and entrepreneur who founded and is Managing Partner of Hagens Berman Sobol Shapiro, a 76-attorney law firm based in Seattle, Washington.

<span class="mw-page-title-main">Patti B. Saris</span> American judge (born 1951)

Patti B. Saris is a United States district judge of the United States District Court for the District of Massachusetts. She is also the former chair of the United States Sentencing Commission.

<span class="mw-page-title-main">Martin Shkreli</span> American financial criminal and businessman (b. 1983)

Martin Shkreli is an American financial criminal and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

<span class="mw-page-title-main">Galena Biopharma</span> American pharmaceutical company

Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.

Andrew Edward Left is an activist, short seller, author and editor of the online investment newsletter Citron Research, formerly StockLemon.com. Under the name Citron Research, Left publishes reports on firms that he claims are overvalued or are engaged in fraud. Left is known for advising investors on short selling and has often appeared on various media outlets such as CNBC and Bloomberg to talk about his opinions on stocks. In 2017, Left was called 'The Bounty Hunter of Wall Street' by The New York Times. Left gained further notoriety following his announced short of GameStop, precipitating a short squeeze that has hurt him and other short sellers in the short term.

Andrew J. Levander is an American lawyer and Chairman of the law firm Dechert, who advises on securities fraud, commercial litigation and white collar criminal defense matters. A former federal prosecutor, he is known for representing numerous prominent Wall Street companies and executives, as well as global businesses facing litigation.

Rothenberg Ventures, known briefly as Frontier Technology Venture Capital, was an American venture capital firm based in San Francisco, California, and founded in 2012 by Mike Rothenberg. It invested in more than 100 companies, including Bustle, Robinhood, Revel Systems, and SpaceX, and focused its investments on virtual reality and other frontier technologies. As of January 2021, the firm's status with the California Franchise Tax Board is "forfeited".

<span class="mw-page-title-main">Benjamin Wey</span> Chinese American businessman

Benjamin Wey is a Chinese-born US Wall Street financier and CEO of New York Global Group (NYGG). He began his financial career as an investment advisor and broker in Oklahoma in the late 1990s. Wey and NYGG were among the most active "facilitators and promoters" of reverse takeovers, which created Special-Purpose Acquisition Companies (SPAC) and allowed small Chinese companies to raise capital on U.S. markets, until reverse takeovers became the subject of a U.S. Securities and Exchange Commission investigation in 2011.

Emmanuel Lemelson is an American-born Greek Orthodox priest, social commentator and hedge fund manager.

Robbins Geller Rudman & Dowd LLP is an American law firm headquartered in San Diego, California. It is a plaintiffs law firm specializing in securities litigation and shareholder rights cases.

Mark (Meir) Nordlicht is the founder and former chief investment officer of Platinum Partners, a U.S. based hedge fund, which came to be known for its unusual investment strategies becoming the subject of a series of controversial criminal and legal actions. According to an indictment, Nordlicht, in addition to the fund's co-CIO and CFO, were accused of running a "ponzi like scheme". A jury acquitted all defendants on the core charges relating to the Ponzi scheme operation, but found two of the lead executives guilty on the lesser charges relating to a bond-rigging scheme. In an unusual move, Judge Brian Cogan, presiding in the case of United States vs. Nordlicht, et al., reversed the jurors' guilty verdicts and acquitted the firm's co-CIO of the lesser charges in a full acquittal, but ordered a new trial to be set for Nordlicht. An appellate court later upheld the convictions.

Reid Collins & Tsai LLP is a national trial law firm with offices in New York, Austin, Dallas, Wilmington, and Washington, D.C. The firm represents plaintiffs in complex commercial litigation on a mixed-fee or contingency-fee basis.

<span class="mw-page-title-main">Alex Mashinsky</span> American technology company founder

Alex Mashinsky is a Ukrainian-born Israeli-American entrepreneur, business executive and alleged fraudster. He is a cofounder and former CEO of Celsius Network, a bankrupt cryptocurrency lending platform.

Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.

References

  1. ↑ "Ligand Pharmaceuticals Incorporated History". Funding Universe.
  2. ↑ "LGND financials". Yahoo! Finance . 2017-12-31. Retrieved September 16, 2018.
  3. ↑ "LGND profile". Yahoo! Finance . December 31, 2020. Retrieved September 6, 2021.
  4. ↑ "About :: Ligand Pharmaceuticals, Inc. (LGND)". Ligand. Retrieved 2018-09-12.
  5. 1 2 3 4 Bigelow, Bruce (March 25, 2011). "San Diego's Ligand Takes Advantage of the Great Recession to Build New Drug Pipeline". Xconomy. Retrieved 13 September 2018.
  6. 1 2 "Priest Urged Investors To 'Run' From Pharma Biz, Jury Hears - Law360". www.law360.com. Retrieved 2022-10-01.
  7. 1 2 3 "Ligand to pay $12.2 million to settle lawsuits". The San Diego Union-Tribune . Retrieved 2018-09-12.
  8. 1 2 "Ligand Announces Recently Filed Shareholder Derivative Lawsuit" . Retrieved 2018-09-12.
  9. 1 2 "Lawsuit for Investors in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over alleged Violations of Securities Laws announced by Shareholders Foundation". GlobeNewswire News Room. Retrieved 2018-09-12.
  10. 1 2 "Ligand Pharmaceuticals Sued for $3.8 Billion Over Bond Terms" . Retrieved 2018-09-12.
  11. ↑ "How the 16 highest-paid CEOs of San Diego public companies made their money". San Diego Union-Tribune. 2019-07-14. Retrieved 2022-10-01.
  12. ↑ "Ligand to Participate in Four Upcoming Investor Conferences". Archived from the original on 2015-07-11.
  13. ↑ "Document". SEC.
  14. ↑ "3 Biotech Stocks That Could Grow Faster than Apple". The Motley Fool. 2015-07-04. Retrieved 11 July 2015.
  15. ↑ "Captisol" . Retrieved 11 July 2015.
  16. ↑ "Ligand Pharmaceuticals Incorporated". Company Histories. 2002. Retrieved 16 September 2018.
  17. ↑ "Ligand loses its listing on Nasdaq". The San Diego Union-Tribune . Retrieved 2018-09-12.
  18. ↑ "Ligand Announces SEC Investigation". www.shareholder.com. September 12, 2005.
  19. ↑ "SEC starts probe into Ligand's accounting". The San Diego Union-Tribune . Retrieved 2018-09-12.
  20. ↑ "Investors Sue Ligand Over Exaggerated Financials". 2016-11-19. Retrieved 2018-09-12.
  21. ↑ "Ligand Pharmaceuticals facing securities class action". Battea Class Action Services. 2016-12-28. Retrieved 2018-09-12.
  22. ↑ "Ligand Pharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Announcing Restatement Of Financial Results". www.prnewswire.com. Retrieved 2018-09-12.
  23. 1 2 Alpert, Bill. "Hedge Fund Alleges SEC Bias in Short-Selling Case". www.barrons.com. Retrieved 2022-10-01.
  24. ↑ "Priest Points Finger At Biotech As SEC Short Sale Trial Wraps - Law360". www.law360.com. Retrieved 2022-10-01.
  25. ↑ "Priest Points Finger At Biotech As SEC Short Sale Trial Wraps - Law360". www.law360.com. Retrieved 2023-01-14.
  26. ↑ "Jury Clears Priest in 'Short-and-Distort' Scheme". CFO. 2021-11-08. Retrieved 2022-10-01.
  27. ↑ "Hedge Fund Priest Beats SEC Short-And-Distort Claims - Law360". www.law360.com. Retrieved 2022-10-01.
  28. ↑ Alpert, Bill. "The SEC Wins Mixed Verdict Against a Short Seller Who Wouldn't Settle". www.barrons.com. Retrieved 2022-10-01.
  29. ↑ "Hedge Fund Priest Seeks Total Victory Over SEC Stock Suit - Law360". www.law360.com. Retrieved 2022-10-01.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.